$0.29 EPS Expected for Inogen Inc (INGN) This Quarter
Wall Street analysts predict that Inogen Inc (NASDAQ:INGN) will post $0.29 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Inogen’s earnings, with estimates ranging from $0.24 to $0.33. Inogen posted earnings per share of $0.16 during the same quarter last year, which indicates a positive year over year growth rate of 81.3%. The business is expected to report its next earnings results after the market closes on Tuesday, November 7th.
On average, analysts expect that Inogen will report full year earnings of $1.20 per share for the current financial year, with EPS estimates ranging from $1.17 to $1.23. For the next financial year, analysts expect that the company will report earnings of $1.30 per share, with EPS estimates ranging from $1.23 to $1.39. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Inogen.
Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.10. Inogen had a net margin of 13.00% and a return on equity of 16.70%. The firm had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. During the same period in the prior year, the firm earned $0.25 earnings per share. The business’s quarterly revenue was up 17.4% compared to the same quarter last year.
A number of equities analysts have issued reports on INGN shares. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $90.00 target price on shares of Inogen in a research report on Tuesday, September 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $108.00 target price on shares of Inogen in a research report on Friday, September 1st. BidaskClub raised Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, J P Morgan Chase & Co upped their target price on Inogen to $102.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Inogen currently has a consensus rating of “Buy” and a consensus price target of $90.80.
Inogen (NASDAQ:INGN) traded up 2.11% during mid-day trading on Friday, hitting $96.65. 107,972 shares of the company were exchanged. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 83.90 and a beta of 0.99. The firm has a 50 day moving average price of $98.17 and a 200 day moving average price of $91.40. Inogen has a 12 month low of $50.24 and a 12 month high of $105.35.
In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total value of $1,283,380.00. Following the transaction, the director now directly owns 7,808 shares of the company’s stock, valued at approximately $715,759.36. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $92.45, for a total value of $231,125.00. Following the completion of the transaction, the executive vice president now directly owns 6,964 shares in the company, valued at $643,821.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,667 shares of company stock worth $7,041,641. 5.31% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new stake in shares of Inogen in the 1st quarter valued at approximately $109,000. Schroder Investment Management Group bought a new stake in shares of Inogen in the 2nd quarter valued at approximately $132,000. Victory Capital Management Inc. increased its holdings in shares of Inogen by 36.1% in the 1st quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after acquiring an additional 459 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after acquiring an additional 443 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Inogen in the 1st quarter valued at approximately $203,000.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/22/0-29-eps-expected-for-inogen-inc-ingn-this-quarter.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.